Dimensional Fund Advisors' $477B Q4 2025 Filing Spreads Across 3,239 Positions With No Stock Above 3.7%
DFA held $476.7B in Q4 2025 across 3,239 unique holdings — the broadest active manager in the top 50. No single stock exceeds 3.7%, making this the anti-concentration 13F among major filers.
Dimensional Fund Advisors filed its Q4 2025 13F showing $476.7 billion across 3,239 unique holdings. The largest position, Nvidia, accounts for just 3.68% of the portfolio. No stock exceeds 4%. In a world where concentrated conviction bets dominate the headlines, DFA runs the opposite playbook: systematic, factor-based diversification at massive scale.
TL;DR
- AUM: $476.7B (Q4 2025)
- Holdings count: 3,239 unique — broadest active manager in the top 50
- Max position weight: 3.68% (Nvidia) — the lowest max-weight among top-30 filers
- Top-5 concentration: 12.6% — far below the 16-25% range of peers
- Factor approach: DFA's signature systematic value/small-cap tilts visible in the breadth
- Healthcare presence: Eli Lilly ($4.1B, 0.85%) and Johnson & Johnson ($3.6B, 0.75%) in top 12
- Berkshire at #12: BRK/B at $3.6B (0.75%) — Buffett's conglomerate fits the value factor tilt
- Whale Score: 69.00
DFA Top 12 Holdings — Q4 2025 ($B)
The Anti-Concentration Strategy
DFA's 3,239 positions with a 3.68% maximum weight is fundamentally different from peers like Capital International (454 holdings, 7.7% top weight) or Capital Research Global (434 holdings, 6.55% top weight). DFA's approach is rooted in academic finance: diversify across factors (value, size, profitability) rather than concentrating in individual names.
The top-5 (NVDA 3.68%, AAPL 3.28%, MSFT 2.69%, AMZN 1.54%, META 1.39%) totals just 12.6% — the lowest among any top-30 filer. Even passive index funds like Vanguard show higher concentration because they weight purely by market cap.
The Value Factor Footprint
JPMorgan at $5.9B (1.24%) and Berkshire Hathaway at $3.6B (0.75%) in the top 12 reflect DFA's value tilt. Both are classic value names that systematic factor portfolios overweight relative to pure market-cap indexing. Johnson & Johnson ($3.6B, 0.75%) adds defensive quality — another DFA factor preference.
DFA Top-5 Concentration vs Peers (% of Portfolio)
What Analysts Might Misread
Misread #1: “Low concentration means no conviction”
DFA's conviction is expressed through factor exposures, not individual stock bets. The portfolio is deliberately diversified — that IS the strategy, not a lack of one.
Misread #2: “DFA is just another index fund”
DFA is not an index fund. It uses proprietary factor models to tilt toward value, small-cap, and high-profitability stocks. The result looks like an index but weights are systematically different from any standard benchmark.
Frequently Asked Questions
What is Dimensional Fund Advisors' investment approach?
DFA uses systematic, factor-based investing rooted in academic research. Portfolios tilt toward value, small-cap, and profitability factors rather than concentrating in individual stocks.
How concentrated is DFA's portfolio?
Minimal. The top holding (Nvidia) is just 3.68%, and the top-5 total 12.6%. With 3,239 positions, DFA is the broadest active manager among top-50 filers.
What is DFA's AUM?
$476.7 billion in 13F AUM as of Q4 2025 across 3,239 unique holdings.
Related Research
Explore all researchThe most useful 2025Q4 question was not just who owned the biggest stocks. It was which large managers rotated the hardest beneath the surface. This scoreboard compares four major 13F portfolios side by side.
Broadcom remained the clearest single-stock anchor across several major 13F portfolios in 2025Q4. The weight, not just the dollar total, explains why AVGO kept showing up at the top of institutional books.
A five-filer comparison shows why Berkshire looked like a conviction allocator while the giant diversified managers kept much broader top books in 2025Q4.
Brookfield Corp /ON/ reported an $80.76B 13F book for 2025Q4, and Brookfield Asset Management dominated the filing at 77.4% of weight. The remaining positions matter, but they read more like supporting pieces than co-equal bets.
Lilly Endowment reported an $84.52B 13F portfolio for 2026Q1, and every dollar of it still sat in Eli Lilly. The filing is unusually simple, which is exactly why it makes such a strong case study in institutional concentration.